NovoCure (NVCR) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 26, 2026
AI-Generated Deep Dive Summary
NovoCure (NVCR) reported a strong financial performance in its Q4 2025 earnings call, with net revenue reaching $655 million for the year, marking an 8% year-over-year growth. The company also highlighted a solid quarterly figure of $174 million, reflecting consistent progress. Notably, international markets drove significant growth, particularly in Germany (10%), France (19%), and Japan (29%). In the U.S., active patient growth in GBM (glioblastoma multiforme) reached 4%, breaking a period of stagnation. These figures underscore NovoCure's ability to expand its market presence and improve access to its innovative therapies.
The company’s gross margin stood at 75% for the year and 76% for the quarter, slightly down from prior years due to higher tariffs and reduced collections. However, adjusted EBITDA remained negative at $34 million annually and $16 million quarterly, signaling ongoing operational challenges despite revenue growth. NovoCure provided forward-looking guidance for 2026, forecasting revenue between $675 million and $705 million—a 3% to 8% increase—and aiming for breakeven or profitability. This outlook reflects the company’s commitment to improving efficiency and scaling its operations.
NovoCure also emphasized its expanding
Verticals
financeinvesting
Originally published on The Motley Fool on 2/26/2026